Design Therapeutics (DSGN) EBITDA Yield: History & Chart

Design Therapeutics, Inc.(DSGN)

Biotechnology · Carlsbad, CA

$11.92-0.50 (-4.03%)

Delayed quote: Oct 6, 2026, 2:49 PM EDT

About Design Therapeutics, Inc.

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

Carlsbad, CA

55 employees

www.designtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pratik Shah

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Design Therapeutics, Inc. (DSGN)	$744.49M	N/A	N/A	N/A	N/A
Apnimed, Inc. (APMD)vs ›	$750.67M	N/A	N/A	N/A	N/A
Achieve Life Sciences, Inc. (ACHV)vs ›	$732.23M	N/A	N/A	N/A	N/A
Candel Therapeutics, Inc. (CADL)vs ›	$731.21M	N/A	N/A	N/A	N/A
Mesa Laboratories, Inc. (MLAB)vs ›	$759.25M	5.47%	6.26%	5.92%	4.44%
Attovia Therapeutics, Inc. (ATTO)vs ›	$763.35M	N/A	N/A	N/A	N/A
Faeth Therapeutics, Inc. (FTH)vs ›	$722.32M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$718.28M	N/A	0.40%	0.67%	0.67%
Avalo Therapeutics, Inc. (AVTX)vs ›	$717.44M	N/A	4.15%	4.09%	4.09%
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$772.90M	N/A	7.18%	23.84%	23.84%

NAME

MARKET CAP

EBITDA YIELD

TTM

Design Therapeutics, Inc. (DSGN)

$744.49M

N/A

Apnimed, Inc. (APMD)vs ›

$750.67M

N/A

Achieve Life Sciences, Inc. (ACHV)vs ›

$732.23M

N/A

Candel Therapeutics, Inc. (CADL)vs ›

$731.21M

N/A

Mesa Laboratories, Inc. (MLAB)vs ›

$759.25M

5.47%

6.26%

5.92%

4.44%

Attovia Therapeutics, Inc. (ATTO)vs ›

$763.35M

N/A

Faeth Therapeutics, Inc. (FTH)vs ›

$722.32M

N/A

Cytek Biosciences, Inc. (CTKB)vs ›

$718.28M

N/A

0.40%

0.67%

Avalo Therapeutics, Inc. (AVTX)vs ›

$717.44M

N/A

4.15%

4.09%

Lexicon Pharmaceuticals, Inc. (LXRX)vs ›

$772.90M

N/A

7.18%

23.84%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

DSGN EBITDA Yield Metrics

DSGN Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics